Literature DB >> 19293635

Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.

Sung Hee Yoon1, Sun Ok Yun, Jung Yong Park, Hee Yeun Won, Eun Kyung Kim, Hyun Jung Sohn, Hyun Il Cho, Tai Gyu Kim.   

Abstract

Increasing importance is being given to the stimulation of Th1 response in cancer immunotherapy because its presence can shift the direction of adaptive immune responses toward protective immunity. Based on chemokine receptor expression, CXCR3(+) CCR4(-) CD4(+) T cells as Th1-type cells were investigated its capacity in monocyte-derived dendritic cell (DC) maturation and polarization, and induction of antigen specific cytotoxic T lymphocytes (CTL) in vitro. The levels of IL-4, IL-5 and IL-10 were decreased to the basal level compared with high production of IFN-gamma, TNF-alpha, and IL-2 in CXCR3+CCR4-CD4+ T cells stimulated with anti-CD3 and anti-CD28 antibodies. Co-incubation of activated CD4(+) or CXCR3(+) CCR4-CD4(+) T cells with DC (CD4(+/) DC or CXCR3(+) CD4(+/) DC, respectively) particularly up-regulated IL-12 and CD80 expression compared with DC matured with TNF-a and LPS (mDC). Although there was no significant difference between the effects of the CXCR3(+) CCR4(-) CD4(+) and CD4(+) T cells on DC phenotype expression, CXCR3(+) CD4(+/) DC in CTL culture were able to expand number of CD8(+) T cells and increased frequencies of IFN-gamma secreting cells and overall cytolytic activity against tumor antigen WT-1. These results demonstrated that the selective addition of CXCR3(+) CCR4(-) CD4(+) T cells to CTL cultures could enhance the induction of CTLs by DC in vitro, and implicated on a novel strategy for adoptive T cell therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293635      PMCID: PMC2679244          DOI: 10.3858/emm.2009.41.3.019

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  33 in total

1.  Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL.

Authors:  Kiley R Prilliman; Edward E Lemmens; Georgia Palioungas; Thomas G Wolfe; James P Allison; Arlene H Sharpe; Stephen P Schoenberger
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

2.  Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses.

Authors:  Juyang Kim; Sun Phil Choi; Soojin La; Jeong-Sun Seo; Kack Kyun Kim; Seok Hyun Nam; Byungsuk Kwon
Journal:  Exp Mol Med       Date:  2003-12-31       Impact factor: 8.718

3.  Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation.

Authors:  Chang H Kim; Kinya Nagata; Eugene C Butcher
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

4.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?

Authors:  Manfred B Lutz; Gerold Schuler
Journal:  Trends Immunol       Date:  2002-09       Impact factor: 16.687

5.  Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response.

Authors:  Gentao Liu; Hiushan Ng; Yasuharu Akasaki; Xiangpeng Yuan; Moneeb Ehtesham; Dong Yin; Keith L Black; John S Yu
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

Review 6.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

7.  Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell.

Authors:  Feng Guang Gao; Vithagna Khammanivong; Wen Jun Liu; Graham R Leggatt; Ian H Frazer; Germain J P Fernando
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

8.  Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

Authors:  Yue Zhang; Daiko Wakita; Kenji Chamoto; Yoshinori Narita; Naoki Matsubara; Hidemitsu Kitamura; Takashi Nishimura
Journal:  Int Immunol       Date:  2006-12-22       Impact factor: 4.823

9.  Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function.

Authors:  Robert L Giuntoli; Jun Lu; Hiroya Kobayashi; Richard Kennedy; Esteban Celis
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

10.  Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Rie Yasuda; Ryuko Watanabe; David Berd; Michael J Mastrangelo; Kenichiro Hasumi
Journal:  Cancer Immunol Immunother       Date:  2003-09-10       Impact factor: 6.968

View more
  12 in total

Review 1.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

2.  Homotypic cell to cell cross-talk among human natural killer cells reveals differential and overlapping roles of 2B4 and CD2.

Authors:  Eun-Ok Kim; Tae-Jin Kim; Nayoung Kim; Sung Tae Kim; Vinay Kumar; Kyung-Mi Lee
Journal:  J Biol Chem       Date:  2010-09-02       Impact factor: 5.157

3.  CXCR3 in T cell function.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

4.  Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor.

Authors:  Tae-Jin Kim; Nayoung Kim; Eun-Ok Kim; Jong-Rip Choi; Jeffrey A Bluestone; Kyung-Mi Lee
Journal:  Immunology       Date:  2010-04-06       Impact factor: 7.397

5.  Recombinant mammaglobin A adenovirus-infected dendritic cells induce mammaglobin A-specific CD8+ cytotoxic T lymphocytes against breast cancer cells in vitro.

Authors:  Huixia Cui; Wenlu Zhang; Wei Hu; Kun Liu; Tong Wang; Nan Ma; Xiaohui Liu; Yunpeng Liu; Youhong Jiang
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

6.  Accumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells.

Authors:  Helena Svensson; Veronica Olofsson; Samuel Lundin; Chakradhar Yakkala; Stellan Björck; Lars Börjesson; Bengt Gustavsson; Marianne Quiding-Järbrink
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

7.  Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.

Authors:  Atsushi Aruga; Nobuhiro Takeshita; Yoshihito Kotera; Ryuji Okuyama; Norimasa Matsushita; Takehiro Ohta; Kazuyoshi Takeda; Masakazu Yamamoto
Journal:  J Transl Med       Date:  2014-03-07       Impact factor: 5.531

8.  A synthetic pathogen mimetic molecule induces a highly amplified synergistic immune response via activation of multiple signaling pathways.

Authors:  Naorem Nihesh; Saikat Manna; Bradley Studnitzer; Jingjing Shen; Aaron P Esser-Kahn
Journal:  Chem Sci       Date:  2021-04-01       Impact factor: 9.825

9.  CCR3, CCR4, CCR5, and CXCR3 expression in peripheral blood CD4+ lymphocytes in gastric cancer patients.

Authors:  Alireza Andalib; Hassan Doulabi; Mohammad Reza Maracy; Abbas Rezaei; Seyed Javad Hasheminia
Journal:  Adv Biomed Res       Date:  2013-03-14

10.  Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse.

Authors:  Jinhyun Kim; Ji Yong Choi; Sung-Hye Park; Seung Hee Yang; Ji Ah Park; Kichul Shin; Eun Young Lee; Hiroshi Kawachi; Hitoshi Kohsaka; Yeong Wook Song
Journal:  Arthritis Res Ther       Date:  2014-06-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.